Lack of clinical usefulness of Das-1 monoclonal antibody and mucin expression as risk markers of gastric carcinoma in patients with gastric intestinal metaplasia.

摘要

Forne et al concluded that the Das-1 monoclonal antibody was not as sensitive as we reported earlier as a premalignant marker for gastric intestinal metaplasia (GIM) associated with gastric cancer. The monoclonal antibody Das-1, developed by us, recognizes the colonic phenotype (type III or incomplete) of GIM, as also confirmed by 3 other independent groups of gastroenterologists and pathologists. By using Helicobacter pylori-associated chronic gastritis with GIM in Japanese patients, we again recently demonstrated a significant correlation of Das-1 positivity to the carcinogenicity in Hpylori-related GIM.